Keep up-to-date with BMS Canada
MONTREAL, QUEBEC – May 17, 2017
HEALTH CANADA APPROVES OPDIVO®(NIVOLUMAB) FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKLatest approval of OPDIVO® marks the fourth indication for the immuno-oncology treatment offering hope for improved survival to more patients
MONTREAL, QUEBEC – March 22, 2017
MONTREAL, QUEBEC – March 14, 2017
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.